A predictive approach was assayed to evaluate the possibility of mutant Amp-C L-lactamase emergence with increased substrate spectrum (including new C-3P quaternary ammonium cephems). The ampC gene encoding the AmpC L-lactamase from Enterobacter cloacae was cloned and expressed in an AmpC-defective strain of E. coli. After the AmpC containing strain was challenged with cefpirome, an ampC variant encoding an enzyme with increased resistance to cefpirome and cefepime was selected. In addition, this variant conferred increased resistance to penicillins and third generation cephalosporins. The complete nucleotide sequence of the gene was determined. The deduced peptide sequence showed a single change with respect to the wild-type gene: valine to glutamic acid at position 318 of the native protein (298 of the mature enzyme). The potential emergence and spread of this type of AmpC variants among pathogens should be considered. z 1998 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.
Introduction
L-Lactamase production is the main and widespread mechanism of resistance to L-lactam antibiotics among Gram-negative bacteria. These enzymes probably have a potential to evolve to enzymes able to hydrolyse almost any new L-lactam molecule. Among L-lactamases, two groups, chromosomally and plasmid-encoded enzymes have extensively been described [1] . Most members of Enterobacteriaceae produce Group I chromosomal cephalosporinases, their inducible expression being regulated according to particular genetic control mechanisms in several species [2] . Ambler Class A L-lactamases, which include plasmid-mediated TEM and SHV enzymes, are constitutively produced. Point mutations in the corresponding structural genes lead either to a widening of the hydrolytic spectrum to extendedspectrum L-lactams or to resistance to the action of L-lactamase inhibitors [1, 3] . Recently, chromosomal ampC genes of Enterobacteriaceae and Pseudomonas aeruginosa have been found to be located on plasmids conferring the`AmpC constitutive spectrum of resistance', including resistance to third-generation cephalosporins and cephamycins and susceptibility to cefpirome, cefepime and carbapenems [4^6] . Moreover, the AmpC-type L-lactamases are naturally resistant to the currently used L-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam. Of particular concern, due to the epidemiogenic features of the genus, is the report of two isolates of Salmonella spp. harbouring plasmid-encoded AmpC L-lactamases [7, 8] . In general, the risk of spreading of the AmpC resistance mechanism among enterobacterial isolates is worrying. An example of this situation may be represented by Enterobacter strains which, frequently isolated from seriously compromised patients, pose a challenge to the design of alternative therapeutic regimes.
The aim of this work was to predict and evaluate the possible appearance of plasmid-mediated ampC gene mutation(s) altering the amino acid AmpC structure, resulting in an eventual enlargement of the spectrum of L-lactam resistance, including resistance to the new C-3P quaternary ammonium cephems.
Materials and methods

Construction of the ampC-plasmid-containing strain
A strain of E. coli harbouring a plasmid containing the ampC-MHN gene, was kindly provided by E. Collatz. Plasmid DNA was puri¢ed and used as template in a polymerase chain reaction (PCR). The gene encoding the chromosomal L-lactamase from Enterobacter cloacae was PCR ampli¢ed. Oligonucleotides E1 (5P-TCGGAATTCCGGAGGATTACT-GATG-3P) and E2 (5P-TTAGTCGACAATGTTT-TACTGTAGCGC-3P) were used, respectively, as forward and reverse primers. Both primers contained a tail with the EcoRI (E1) and SalI (E2) recognition sequences (in bold type). Since oligonucleotides E1 and E2 prime, respectively, at the origin and at the end of the structural gene, all regulatory signals from the original gene were eliminated by the cloning strategy. In addition, primer E1 contains a mismatched base (underlined) to generate a consensus E. coli ribosome binding site. The expected ampli¢ed product of ca. 1200 bp was veri¢ed by agarose gel electrophoresis. The EcoRI/SalI-digested PCR product was ligated with the EcoRI/SalI-digested vector pBGS18 3 [9] , which confers resistance to kanamycin. In order to avoid interferences with the host-AmpC enzyme, the Escherichia coli K-12 strain MI1443 (ampC deleted mutant) [10] was used as recipient for the hybrid plasmid. The ligation mixture was introduced by transformation in CaCl P competent MI1443 cells. Transformants were selected onto agar plates containing kanamycin (30 Wg ml 3I ) and ampicillin (80 Wg ml 3I ). Several clones were selected, puri¢ed, and their plasmid content analysed. The presence of the desired hybrid plasmid was veri¢ed by restriction analysis, PCR, and by sequencing the whole cloned ampC gene. The nucleotide sequence has been deposited at the EMBL Nucleotide Sequence Database under the accession number AJ005633.
Selection of the cefpirome-resistant variant
To obtain molecular variants with increased activity against new cephalosporins, the strain MI1443 (pBGMHN) was submitted to step-wise selection experiments using cefpirome as selecting antibiotic. The experiment was performed by a broth macrodilution method with daily transfer of an adjusted 1^5U10 S CFU ml 3I inoculum to fresh media containing two-fold serial dilutions of cefpirome. Serial transfer was continued until no visible growth was observed. Plasmid DNA was extracted from an aliquot of the last tube that exhibited turbidity. The DNA was introduced by transformation in the strain MI1443 and transformants were isolated on LB agar plates containing 30 Wg ml 3I of kanamycin (ampicillin was avoided to overcome the possible counterselection of mutants). Several colonies were selected and a ¢rst screening of antibiotic susceptibility to amoxicyllin (AMX), amoxycillin-clavulanate (AMC), piperacillin (PIP), piperacillin-tazobactam (PTZ), cefotaxime (CTX), ceftazidime (CAZ), cefepime (FEP), cefpirome (CPR), cefoxitin (FOX), imipenem (IMP) and meropenem (MEM) was per- formed by the E-test (data not shown). One clone, 7.6, was chosen for further study as it presented the higher levels of resistance to the antibiotics tested. Table 1 shows the resistance phenotypes (obtained by agar dilution according to the NCCLS guidelines) of the strain MI1443 containing the vector pBGS-18 3 (lacking the ampC gene), the wild-type plasmid pBGMHN, or the mutant pBGMHN-7.6. The mutant AmpC enzyme was able to confer resistance to cefepime and cefpirome and also had increased MICs to cefotaxime and ceftazidime. Interestingly, the MIC to cefoxitin was 4-fold decreased. Activity on carbapenems, imipenem and meropenem remained unchanged.
Results and discussion
Phenotypic characterisation of the mutant
Genotypic characterisation of the mutant
The increased resistance conferred by the plasmid pBGMHN-7.6 could be theoretically due to mutations in the promoter region, mutations on the structural ampC gene or mutations that increase the plasmid copy number. To verify that this resistance is actually due to mutations on the structural ampC gene, the ampC region from this less susceptible variant was ampli¢ed by the same PCR procedure and again cloned in pBGS18 3 , with identical strategy as before. The ampC-containing fragment from clone 7.6 was able to confer the same increased resistance to cefepime and cefpirome as the original mutant strain. This indicated that mutation(s) responsible for cephalosporins resistance was/were in the structural ampC gene. The plasmid harbouring the mutant ampC gene was named pBGMHN-7.6. To characterise the mutation(s) responsible for increased resistance, the whole ampC-7.6 structural gene was sequenced using the reverse and universal primers and ampC internal oligonucleotides. The obtained sequence was compared with the wild type obtained before the cefpirome challenge. This comparison revealed a single base replacement at codon 318 of the native protein which corresponds to amino acid position 298 in the mature protein. The amino acid change was Val QIV (GTG) to Glu (GAG).
Structural analysis
Val PWV is located on a short segment of L-strand on an outer edge of the AmpC structure. The residue itself is distant from the catalytic site, being 18.1 A î from the OQ of the catalytic Ser TR (Fig. 1) . The residue points towards the centre of a small hydrophobic cluster in AmpC, making van der Waals and hydrophobic' contacts with the side chain of residue Thr IIQ , the CL of Arg IRV , the main chain CK of Thr IRT and Thr IRU , and the side chain of Trp PTH and Ile PTP (Fig. 2) . The substitution of Val PWV by a Glu is unlikely to have a direct e¡ect on ligand recognition, as for instance by polar or non-polar bonds with the substrate, or even by interacting with substrate binding residues. This is because of the long distance from the Val PWV to the catalytic site. Of course, a longrange electrostatic e¡ect of the glutamic acid cannot be ruled out, but even this seems unlikely. Instead, the interaction is probably indirect. At present, the form of this indirect interaction can only be a matter of speculation. Still, several interesting points may be noted. Val PWV is at the centre of a small hydrophobic patch and is largely buried from solvent. The substitution of glutamic acid for the valine at this position should disrupt the local structure nucleated by this mini-hydrophobic`core' [11] . This disruption may increase the overall £exibility of the enzyme, broadening its spectrum of action including traditionally resistant substrates. At the same time, the substitution, coming well away from the central hydrophobic core of AmpC, is probably not so disruptive as to unfold the enzyme. This would explain why AmpC enzymes do not have a Glu at position 298. Small hydrophobic residues like valine are highly conserved here, and indeed the nature of the surrounding residues (Fig. 2) is also highly conserved. Replacement of the valine would thus be costly as far as the stability of the enzyme is concerned. Thus, only under the pressure of antibiotic action would this substitution arise. It may be interesting to undertake further enzymatic and stability studies to test this hypothesis [12] . Overall, the long distance of this substitution from the catalytic site, and its residue environment, resemble resistance mutations in HIV-1 protease that have been observed to arise during the course of protease-inhibitor treatment against AIDS [13] .
Concluding remarks
Evolution of L-lactamases represents a paramount example of adaptive behaviour by means of amino acid changes yielding more e¤cacious enzymes. The objective of this work was to obtain some experimentally-based prediction on the possible emergence of`extended spectrum' AmpC L-lactamases, considering the increasing use of antibiotics active on strains harbouring these enzymes. Resistance mediated by AmpC enzymes is dependent on the modi¢-cation of genes that control the amount of enzyme produced [14] . In this work we present an AmpC molecular variant obtained in vitro after a challenge with cefpirome as selecting agent, that confers considerable levels of resistance to both cefepime and cefpirome (64 and 256 times increase in MIC in comparison with the control strain harbouring the wildtype hybrid plasmid).
Because of the higher activity of the new C-3P quaternary ammonium cephalosporin compounds, cefepime and cefpirome, on AmpC derepressed mutants compared with ceftazidime or cefotaxime, they have been considered poor selectors for resistance in the hospital setting [15^17]. This paper opens the possibility that these antibiotics may select AmpC variants with cross-resistance to all available cephalosporins. Interestingly, cephamycins (as cefoxitin), classically considered susceptible to AmpC, decrease their susceptibility in the 7.6 mutant, reducing the MIC from 32 to 8 Wg ml 3I . The possible emergence of isolates harbouring a resistance mechanism like this type of`extendedspectrum chromosomal enzymes' in the clinical setting that could be selected during prolonged treatments with the novel C-3P quaternary ammonium compounds remains to be evaluated.
